You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

shr6390

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial (SHR6390)

Not yet recruiting
  • Breast Cancer
  • SHR6390
  • (no location specified)
Aug 24, 2022

Healthy Volunteers Trial in Melbourne (SHR6390)

Completed
  • Healthy Volunteers
  • SHR6390
  • Melbourne, Western Australia, Australia
    Linear Clinical Research
Jul 13, 2022

Advanced Breast Cancer, Metastatic Breast Cancer Trial in Tianjin (SHR6390, famitinib)

Recruiting
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Tianjin, Tianjin, China
    Breast Oncology, Tianjin Medical University Cancer Institute and
Apr 6, 2022

Metastatic Breast Cancer Trial in Zhengzhou (Pyrotinib, SHR6390)

Active, not recruiting
  • Metastatic Breast Cancer
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Mar 7, 2022

Pancreatic Cancer Trial in Shanghai (SHR6390, Nab-paclitaxel, Gemcitabine)

Not yet recruiting
  • Pancreatic Cancer
  • SHR6390
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiaotong University School of Medicine
Jan 10, 2022

Metastatic Breast Cancer Trial in Zhengzhou (Famitinib, SHR6390, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jan 25, 2022

Healthy Volunteers Trial in Wuhan (SHR6390)

Completed
  • Healthy Volunteers
  • SHR6390
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Oct 11, 2021

Breast Cancer, Metastatic Cancer Trial in Shanghai (SHR7390, Famitinib, SHR3162)

Recruiting
  • Breast Cancer
  • Metastatic Cancer
  • Shanghai, Shanghai, China
    Cancer Hospital Affiliated to Fudan University
Jul 22, 2022

Breast Cancer, Metastatic Cancer Trial (SHR-1316, SHR6390, Nab paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Metastatic Cancer
  • (no location specified)
Jan 11, 2022

Advanced Breast Cancer Trial in Beijing (SHR6390, Placebo, Fulvestrant)

Active, not recruiting
  • Advanced Breast Cancer
  • SHR6390
  • +2 more
  • Beijing, Beijing, China
    Chinese Academy of Medical Science
May 31, 2021

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer Trial

Enrolling by invitation
  • Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stageļ¼ŒFemale Breast Cancer
  • SHR6390
  • placebo
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 20, 2021

Advanced Breast Cancer Trial in China (SHR6390, Letrozole or anastrozole or Fulvestrant)

Active, not recruiting
  • Advanced Breast Cancer
  • SHR6390
  • Letrozole or anastrozole or Fulvestrant
  • Ha'erbin, Heilongjiang, China
  • +3 more
May 31, 2021

Hepatic Impairment, Healthy Participants Trial (SHR6390)

Not yet recruiting
  • Hepatic Impairment
  • Healthy Participants
  • SHR6390
  • (no location specified)
Nov 15, 2020

Breast Cancer, HER2-positive Breast Cancer, ER-positive Breast Cancer Trial (SHR6390, Anastrozole, Pyrotinib)

Unknown status
  • Breast Cancer
  • +2 more
  • SHR6390
  • +3 more
  • (no location specified)
Jan 17, 2020

Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Jinan (Pyrotinib, SHR6390, Letrozole)

Unknown status
  • Metastatic Breast Cancer
  • HER2-positive Breast Cancer
  • Jinan, China
    Breast Cancer Center, Shandong Cancer Hospital Affiliated to Sha
Sep 18, 2019

CRC, HCC, NSCLC Trial (SHR-1210, SHR6390)

Unknown status
  • CRC
  • +2 more
  • (no location specified)
Jul 24, 2018